Literature DB >> 25110297

Regulatory framework of pharmaceutical compounding and actual developments of legislation in Europe.

Paola Minghetti1, Doriana Pantano2, Chiara Grazia Milena Gennari3, Antonella Casiraghi4.   

Abstract

Pharmaceutical preparations are medicines that the pharmacist makes for the special needs of the patients that the pharmaceutical industry cannot comply for economic and logistic reasons. Pharmacy compounding is still an important component of pharmacy practice and a valuable therapeutical service that is an integrant part of the modern health care system, but its legislation is not harmonized among European and US countries. In 2011 the Committee of Ministers of the Council of Europe has adopted a Resolution on quality and safety assurance requirements for medicinal products prepared in pharmacies for the special needs of patients. Aim of this resolution is to harmonize quality assurance and standards for pharmacy-made medicinal products among European countries and to pass the gap in quality assurance and standards between preparation in pharmacies and medicines prepared by the pharmaceutical industry. This article will analyze the actual rules and technical norms that regulate compounding activity and the expectations resultants from the new European and US laws.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Extemporaneous; Pharmaceutical preparations; Pharmacy compounding; Regulation; Resolution

Mesh:

Year:  2014        PMID: 25110297     DOI: 10.1016/j.healthpol.2014.07.010

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  11 in total

1.  Making individualized drugs a reality.

Authors:  Huub Schellekens; Mohammed Aldosari; Herre Talsma; Enrico Mastrobattista
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

2.  Optimization of sporulation and purification methods for sporicidal efficacy assessment on Bacillus spores.

Authors:  Liang Li; Jinshan Jin; Haijing Hu; Ian F Deveau; Steven L Foley; Huizhong Chen
Journal:  J Ind Microbiol Biotechnol       Date:  2022-07-30       Impact factor: 4.258

3.  Suspected adverse reaction to compounded preparations prescribed for weight loss: two cases of cerebral venous thrombosis.

Authors:  Beatrice Mainoli; Mariana Carvalho Dias; Patricia Canhão; Mário Miguel Rosa
Journal:  BMJ Case Rep       Date:  2020-03-31

Review 4.  A comparative review of Haute Autorité de Santé and National Institute for Health and Care Excellence health technology assessments of Ikervis® to treat severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes.

Authors:  Yasmina Iffet Eroglu
Journal:  J Mark Access Health Policy       Date:  2017-08-03

5.  Hospital and Community Pharmacists' Perceptions of Which Competences Are Important for Their Practice.

Authors:  Jeffrey Atkinson; Antonio Sánchez Pozo; Dimitrios Rekkas; Daisy Volmer; Jouni Hirvonen; Borut Bozic; Agnieska Skowron; Constantin Mircioiu; Roxana Sandulovici; Annie Marcincal; Andries Koster; Keith A Wilson; Chris van Schravendijk; Roberto Frontini; Richard Price; Ian Bates; Kristien De Paepe
Journal:  Pharmacy (Basel)       Date:  2016-06-15

6.  The Extent of Extemporaneous Preparation and Regulatory Framework of Extemporaneous Compounding in Latvia.

Authors:  Olga Kiseļova; Baiba Mauriņa; Venta Šidlovska; Jānis Zvejnieks
Journal:  Medicina (Kaunas)       Date:  2019-08-26       Impact factor: 2.430

7.  Prevalence, determinants, and characteristics of extemporaneous compounding in Jordanian pharmacies.

Authors:  Hatim S AlKhatib; Sara Jalouqa; Nour Maraqa; Anna Ratka; Eman Elayeh; Suha Al Muhaissen
Journal:  BMC Health Serv Res       Date:  2019-11-08       Impact factor: 2.655

8.  Classification of WHO Essential Oral Medicines for Children Applying a Provisional Pediatric Biopharmaceutics Classification System.

Authors:  Jose-Manuel delMoral-Sanchez; Isabel Gonzalez-Alvarez; Marta Gonzalez-Alvarez; Andres Navarro; Marival Bermejo
Journal:  Pharmaceutics       Date:  2019-10-31       Impact factor: 6.321

9.  Data on the stability of darunavir/cobicistat suspension after tablet manipulation.

Authors:  D Zanon; A Manca; A De Nicolò; A D'Avolio; U M Musazzi; F Cilurzo; N Maximova; C Tomasello; P Minghetti
Journal:  Data Brief       Date:  2020-04-12

Review 10.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.